Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
CC214-1
Cat. No.:
OB0225LY-0288
Appearance:
Solid
Purity:
≥97%
Identity:
Confirmed by NMR, HPLC, and LC-MS.
Size:
Product Overview
Description:
CC214-1 is an mTOR inhibitor with anticancer activity that inhibits protein translation and induces autophagy.
Synonym:
1021920-32-0; 6-(4-(1H-1,2,4-Triazol-5-yl)phenyl)-1-(2-(tetrahydro-2H-pyran-4-yl)ethyl)-1,3-dihydro-2H-imidazo[4,5-b]pyrazin-2-one; 6-(4-(1H-1,2,4-Triazol-3-yl)phenyl)-1-(2-(tetrahydro-2H-pyran-4-yl)ethyl)-1,3-dihydro-2H-imidazo[4,5-b]pyrazin-2-one
CAS No.:
1021920-32-0
Compound CID:
66699750
Formula:
C20H21N7O2
Formula Weight:
391.43
Specification
Relative Density:
1.326 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
CC214-1 can be used as a research tool to explore mTOR kinase biology.
Library Information
Targets:
PI3K/Akt/mTOR pathway
Receptors:
mTOR
Pathways:
PI3K/Akt/mTOR signaling; Autophagy
Plate Number:
AOCL-4
Plate Location:
f7
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10 mM DMSO
